Cargando…
Lithium and Therapeutic Targeting of GSK-3
Lithium salts have been in the therapeutic toolbox for better or worse since the 19th century, with purported benefit in gout, hangover, insomnia, and early suggestions that lithium improved psychiatric disorders. However, the remarkable effects of lithium reported by John Cade and subsequently by M...
Autores principales: | Snitow, Melinda E., Bhansali, Rahul S., Klein, Peter S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7910927/ https://www.ncbi.nlm.nih.gov/pubmed/33525562 http://dx.doi.org/10.3390/cells10020255 |
Ejemplares similares
-
GSK-3 as potential target for therapeutic intervention in cancer
por: McCubrey, James A., et al.
Publicado: (2014) -
Gsk3 Signalling and Redox Status in Bipolar Disorder: Evidence from Lithium Efficacy
por: Luca, Antonina, et al.
Publicado: (2016) -
GSK3 Is a Central Player in Retinal Degenerative Diseases but a Challenging Therapeutic Target
por: Hottin, Catherine, et al.
Publicado: (2022) -
Mechanisms and Therapeutic Implications of GSK-3 in Treating Neurodegeneration
por: Rippin, Ido, et al.
Publicado: (2021) -
Inhibition of GSK3 by lithium, from single molecules to signaling networks
por: Freland, Laure, et al.
Publicado: (2012)